Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Urged To Change OTC Monograph System, But Not In Midstream

This article was originally published in The Tan Sheet

Executive Summary

“Moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades,” CHPA head Scott Melville says at an FDA public hearing. Other stakeholder s explain how the monograph system has failed industry and consumers.

Advertisement

Related Content

FDA Lifts Curtain On Homeopathics Regulatory Evaluation With Public Hearing
FDA Lifts Curtain On Homeopathics Regulatory Evaluation With Public Hearing
Sunscreen Ingredient TEA Decisions Highlight Challenges Of NDA Scale
TEAs Fail To Sweeten OTC Monograph Process, Brew Trouble For New Ingredients
TEAs Fail To Sweeten OTC Monograph Process, Brew Trouble For New Ingredients
Firms Consult FDA, Add “Do Not Use” For Under 4 To Pediatric Cold Products
FDA Floats Eliminating Multi-Ingredient Pediatric Cold Products
FDA Review Of Children’s Cough/Cold OTCs Has Broader Implications

Topics

Advertisement
UsernamePublicRestriction

Register

PS106828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel